Global Primary Hyperoxaluria Treatment Market Report and Forecast 2023-2031

Global Primary Hyperoxaluria Treatment Market Report and Forecast 2023-2031

Global Primary Hyperoxaluria Treatment Market Outlook

The global primary hyperoxaluria treatment market is expected to grow at a CAGR of 3.72% during the forecast period of 2023-2031. The market is anticipated to reach USD 25.35 million by 2031, driven by the increasing prevalence of primary hyperoxaluria and the growing demand for effective treatments.

Primary Hyperoxaluria Treatment Market: Introduction

Primary hyperoxaluria is a rare genetic disorder that results in the accumulation of oxalate in the body, leading to the formation of kidney stones and other complications. The lack of effective treatments for primary hyperoxaluria has been a major challenge for healthcare providers and researchers worldwide. The global primary hyperoxaluria treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. The report covers the market for primary hyperoxaluria treatment and provides a detailed analysis of the market size, growth, and trends.

The primary hyperoxaluria treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as enzyme replacement therapy and gene therapy, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.

Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of primary hyperoxaluria, potentially improving patient outcomes and reducing healthcare costs. As a result, the global primary hyperoxaluria treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.

Primary Hyperoxaluria Epidemiology

Primary hyperoxaluria is a rare inherited disorder that affects the metabolism of oxalate, leading to the formation of kidney stones and other complications. The prevalence of primary hyperoxaluria is estimated to be higher in Europe and North America, with an estimated prevalence of 1-3 cases per 100,000 people.

The disease is usually diagnosed in childhood or early adulthood, and it is characterized by recurrent kidney stones, nephrocalcinosis, and renal failure. Currently, there is no cure for primary hyperoxaluria, and the available treatments only provide symptomatic relief.

The incidence of primary hyperoxaluria varies across different regions of the world. The disease is more common in certain populations, such as those of European ancestry, and less common in others, such as those of Asian and African descent.

Primary Hyperoxaluria Treatment Market Segmentations

The market can be categorised into type, diagnosis method, treatment method, treatment channel, and major region.

Market Breakup by Type

  • Primary Hyperoxaluria Type I
  • Primary Hyperoxaluria Type II
  • Primary Hyperoxaluria Type II
Market Breakup by Diagnosis Method
  • Urine Tests
  • Blood Tests
  • Stone Analysis
  • Kidney X-rays, Ultrasound or Computerized Tomography (CT) Scan
  • DNA Testing
  • Kidney Biopsy
  • Echocardiogram
  • Eye Exam
  • Bone Marrow Biopsy
  • Liver Biopsy
Market Breakup by Treatment Method
  • Medications
  • Potassium Citrate
  • Thiazide Diuretics
  • Vitamin Supplements
  • Lumasiran
  • High Fluid Intake
  • Dietary Changes
  • Kidney Stone Management
  • Dialysis and Transplantation
Market Breakup by Treatment Channel
  • Public
  • Private
Primary Hyperoxaluria Treatment Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Primary Hyperoxaluria Treatment Market Scenario

The primary hyperoxaluria treatment market is expected to grow steadily during the forecast period, driven by the increasing prevalence of the disorder and the growing demand for effective treatments.

North America dominates the primary hyperoxaluria treatment market, followed by Europe and the Asia Pacific. The high prevalence of primary hyperoxaluria in North America and Europe, coupled with the favorable reimbursement policies, is driving the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about primary hyperoxaluria and the rising healthcare expenditure in the region.

The market is highly fragmented, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for primary hyperoxaluria has led to the emergence of many companies focusing on the development of innovative therapies for this disorder. The key players in the market are investing heavily in research and development activities to introduce novel treatments and gain a competitive edge in the market.

Key Players in the Global Primary Hyperoxaluria Treatment Market

The report gives an in-depth analysis of the key players involved in the primary hyperoxaluria treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Alnylam Pharmaceuticals
  • Tecoland Corporation
  • Zhejiang Tianxin Pharmaceuticals Co.
  • Takeda Pharmaceuticals
  • Wuxi Further Pharmaceutical Co Ltd
  • Genentech
  • OxThera
  • Dicerna Pharmaceuticals, Inc.
  • Allena Pharmaceuticals


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Primary Hyperoxaluria Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop- out Analysis
7.3 Awareness and Prevention Gaps
8 Global Primary Hyperoxaluria Treatment Market
8.1 Global Primary Hyperoxaluria Treatment Market Overview
8.2 Global Primary Hyperoxaluria Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Historical Primary Hyperoxaluria Market Value (2016-2022)
8.2.1.2 Global Forecast Primary Hyperoxaluria Market Value (2023-2031)
8.2.2 Global Primary Hyperoxaluria Treatment Market by Type
8.2.2.1 Market Overview
8.2.2.1.1 Primary Hyperoxaluria Type I
8.2.2.1.2 Primary Hyperoxaluria Type II
8.2.2.1.3 Primary Hyperoxaluria Type III
8.2.3 Global Primary Hyperoxaluria Treatment Market by Diagnosis Method
8.2.3.1 Market Overview
8.2.3.1.1 Urine Tests
8.2.3.1.2 Blood Tests
8.2.3.1.3 Stone Analysis
8.2.3.1.4 Kidney X-ray, Ultrasound or Computerized Tomography (CT) Scan
8.2.3.1.5 DNA Testing
8.2.3.1.6 Kidney Biopsy
8.2.3.1.7 Echocardiogram
8.2.3.1.8 Eye Exam
8.2.3.1.9 Bone Marrow Biopsy
8.2.3.1.10 Liver Biopsy
8.2.4 Global Primary Hyperoxaluria Treatment Market by Treatment Method
8.2.4.1 Market Overview
8.2.4.1.1 Medications
8.2.4.1.1.1 Potassium Citrate
8.2.4.1.1.2 Thiazide Diuretics
8.2.4.1.1.3 Vitamin Supplements
8.2.4.1.1.4 Lumasiran
8.2.4.1.2 High Fluid Intake
8.2.4.1.3 Dietary Changes
8.2.4.1.4 Kidney Stone Management
8.2.4.1.5 Dialysis and Transplantation
8.2.5 Global Primary Hyperoxaluria Treatment Market by Treatment Channel
8.2.5.1 Market Overview
8.2.5.1.1 Public
8.2.5.1.2 Private
8.2.6 Global Primary Hyperoxaluria Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Latin America
8.2.6.1.5 Middle East and Africa
9 North America Primary Hyperoxaluria Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Primary Hyperoxaluria Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Primary Hyperoxaluria Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Primary Hyperoxaluria Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Primary Hyperoxaluria Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Primary Hyperoxaluria Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Alnylam Pharmaceuticals, Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Tecoland Corporation
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Zhejiang Tianxin Pharmaceutical Co.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Takeda Pharmaceuticals
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Wuxi Further Pharmaceutical Co Ltd
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Genentech
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 OxThera
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Dicerna Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Allena Pharmaceuticals
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
16 Primary Hyperoxaluria Treatment Market- Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings